🇺🇸 FDA
Pipeline program

Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Mirikizumab, Mirikizumab, to match Tirzepatide, Tirzepatide, Mirikizumab, Tirzepatide

I6T-MC-AMCE

Phase 3 small_molecule active

Quick answer

Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Mirikizumab, Mirikizumab, to match Tirzepatide, Tirzepatide, Mirikizumab, Tirzepatide for Obesity or Overweight, Crohn’s Disease is a Phase 3 program (small_molecule) at Eli Lilly Co. with 1 ClinicalTrials.gov record(s).

Program details

Company
Eli Lilly Co.
Indication
Obesity or Overweight, Crohn’s Disease
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials